Duavive conjugated estrogens/bazedoxifene regulatory update

EMA's CHMP recommended approval of Duavive conjugated estrogens/bazedoxifene from Pfizer to treat estrogen deficiency in postmenopausal women for whom progestin-containing therapy is inappropriate. FDA approved the drug as Duavee last year to treat moderate to severe vasomotor symptoms (VMS) associated with menopause in non-hysterectomized women and to prevent postmenopausal osteoporosis (see BioCentury, Oct. 14, 2013). ...